Orbactiv oritavancin regulatory update

EMA’s CHMP recommended approval of IV Orbactiv oritavancin from The Medicines Co. to treat acute bacterial skin and skin structure infections (ABSSSIs) caused by Gram-positive bacteria, including meth...